Tirzepatide

Tirzepatide, known also as LY3298176, represents a groundbreaking development in the pharmacological management of type 2 diabetes (T2D) and obesity. It’s a synthetic peptide that functions as a dual agonist for both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This dual mechanism is significant because it mimics the effects of endogenous GIP while simultaneously promoting cAMP synthesis at the GLP-1 receptor, leading to a synergistic effect. This results in enhanced insulin response and reduced glucagon levels, outperforming the impact of either GIP or GLP-1 therapies when used independently.

Tirzepatide is a 39 amino acid long peptide, which includes a C20 fatty di-acid moiety. This design grants it an extended duration of action, allowing for a once-weekly dosing regimen in humans. Its efficacy and safety in improving blood sugar control have led to its approval by the United States Food and Drug Administration (USFDA) in May 2022 for treating T2D. This marked it as the first dual GLP-1 and GIP receptor agonist for this purpose.

FOR RESEARCH USE ONLY

Tirzepatide as a novel effective and safe strategy for treating obesity

Tirzepatide for overweight and obesity management

Tirzepatide for Obesity Treatment and Diabetes Prevention